Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 625 to 631 of 631 entries
Sorted by: Best Match Show Resources per page
Using Social Media for Peer-to-Peer Cancer Support: Interviews With Young Adults With Cancer.

JMIR cancer

Lazard AJ, Collins MKR, Hedrick A, Varma T, Love B, Valle CG, Brooks E, Benedict C.
PMID: 34473063
JMIR Cancer. 2021 Sep 02;7(3):e28234. doi: 10.2196/28234.

BACKGROUND: Web-based social support can address social isolation and unmet support needs among young adults with cancer (aged 18-39 years). Given that 94% of young adults own and use smartphones, social media can offer personalized, accessible social support among...

Cite
Lazard AJ, Collins MKR, Hedrick A, et al. Using Social Media for Peer-to-Peer Cancer Support: Interviews With Young Adults With Cancer. JMIR Cancer. 2021;7(3):e28234doi: 10.2196/28234.
Lazard, A. J., Collins, M. K. R., Hedrick, A., Varma, T., Love, B., Valle, C. G., Brooks, E., & Benedict, C. (2021). Using Social Media for Peer-to-Peer Cancer Support: Interviews With Young Adults With Cancer. JMIR cancer, 7(3), e28234. https://doi.org/10.2196/28234
Lazard, Allison J, et al. "Using Social Media for Peer-to-Peer Cancer Support: Interviews With Young Adults With Cancer." JMIR cancer vol. 7,3 (2021): e28234. doi: https://doi.org/10.2196/28234
Lazard AJ, Collins MKR, Hedrick A, Varma T, Love B, Valle CG, Brooks E, Benedict C. Using Social Media for Peer-to-Peer Cancer Support: Interviews With Young Adults With Cancer. JMIR Cancer. 2021 Sep 02;7(3):e28234. doi: 10.2196/28234. PMID: 34473063; PMCID: PMC8446843.
Copy Download .nbib Format: NLM
Trends in environmental and toxicity research on organic ultraviolet filters: A scientometric review.

The Science of the total environment

Carve M, Allinson G, Nugegoda D, Shimeta J.
PMID: 33940738
Sci Total Environ. 2021 Jun 15;773:145628. doi: 10.1016/j.scitotenv.2021.145628. Epub 2021 Feb 05.

In recent decades, the potential toxicological and environmental effects of organic ultraviolet filters (OUVF) have received growing attention. The number of studies in this area has increased; however, presently there is no scientometric perspective addressing this topic. The purpose...

Cite
Carve M, Allinson G, Nugegoda D, et al. Trends in environmental and toxicity research on organic ultraviolet filters: A scientometric review. Sci Total Environ. 2021;773:145628doi: 10.1016/j.scitotenv.2021.145628.
Carve, M., Allinson, G., Nugegoda, D., & Shimeta, J. (2021). Trends in environmental and toxicity research on organic ultraviolet filters: A scientometric review. The Science of the total environment, 773145628. https://doi.org/10.1016/j.scitotenv.2021.145628
Carve, Megan, et al. "Trends in environmental and toxicity research on organic ultraviolet filters: A scientometric review." The Science of the total environment vol. 773 (2021): 145628. doi: https://doi.org/10.1016/j.scitotenv.2021.145628
Carve M, Allinson G, Nugegoda D, Shimeta J. Trends in environmental and toxicity research on organic ultraviolet filters: A scientometric review. Sci Total Environ. 2021 Jun 15;773:145628. doi: 10.1016/j.scitotenv.2021.145628. Epub 2021 Feb 05. PMID: 33940738.
Copy Download .nbib Format: NLM
Documentation of Caregivers as a Standard of Care.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Applebaum AJ, Kent EE, Lichtenthal WG.
PMID: 33945287
J Clin Oncol. 2021 Jun 20;39(18):1955-1958. doi: 10.1200/JCO.21.00402. Epub 2021 May 04.

No abstract available.

Cite
Applebaum AJ, Kent EE, Lichtenthal WG. Documentation of Caregivers as a Standard of Care. J Clin Oncol. 2021;39(18):1955-1958doi: 10.1200/JCO.21.00402.
Applebaum, A. J., Kent, E. E., & Lichtenthal, W. G. (2021). Documentation of Caregivers as a Standard of Care. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(18), 1955-1958. https://doi.org/10.1200/JCO.21.00402
Applebaum, Allison J, et al. "Documentation of Caregivers as a Standard of Care." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,18 (2021): 1955-1958. doi: https://doi.org/10.1200/JCO.21.00402
Applebaum AJ, Kent EE, Lichtenthal WG. Documentation of Caregivers as a Standard of Care. J Clin Oncol. 2021 Jun 20;39(18):1955-1958. doi: 10.1200/JCO.21.00402. Epub 2021 May 04. PMID: 33945287; PMCID: PMC8260920.
Copy Download .nbib Format: NLM
Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset.

Journal of immunology (Baltimore, Md. : 1950)

Law JC, Girard M, Chao GYC, Ward LA, Isho B, Rathod B, Colwill K, Li Z, Rini JM, Yue FY, Mubareka S, McGeer AJ, Ostrowski MA, Gommerman JL, Gingras AC, Watts TH.
PMID: 34903642
J Immunol. 2022 Jan 15;208(2):429-443. doi: 10.4049/jimmunol.2100727. Epub 2021 Dec 13.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces T cell, B cell, and Ab responses that are detected for several months in recovered individuals. Whether this response resembles a typical respiratory viral infection is a matter of debate. In...

Cite
Law JC, Girard M, Chao GYC, et al. Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset. J Immunol. 2021;208(2):429-443doi: 10.4049/jimmunol.2100727.
Law, J. C., Girard, M., Chao, G. Y. C., Ward, L. A., Isho, B., Rathod, B., Colwill, K., Li, Z., Rini, J. M., Yue, F. Y., Mubareka, S., McGeer, A. J., Ostrowski, M. A., Gommerman, J. L., Gingras, A. C., & Watts, T. H. (2022). Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset. Journal of immunology (Baltimore, Md. : 1950), 208(2), 429-443. https://doi.org/10.4049/jimmunol.2100727
Law, Jaclyn C, et al. "Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset." Journal of immunology (Baltimore, Md. : 1950) vol. 208,2 (2022): 429-443. doi: https://doi.org/10.4049/jimmunol.2100727
Law JC, Girard M, Chao GYC, Ward LA, Isho B, Rathod B, Colwill K, Li Z, Rini JM, Yue FY, Mubareka S, McGeer AJ, Ostrowski MA, Gommerman JL, Gingras AC, Watts TH. Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset. J Immunol. 2022 Jan 15;208(2):429-443. doi: 10.4049/jimmunol.2100727. Epub 2021 Dec 13. PMID: 34903642.
Copy Download .nbib Format: NLM
Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies.

Cancers

Gopalakrishnapillai A, Correnti CE, Pilat K, Lin I, Chan MK, Bandaranayake AD, Mehlin C, Kisielewski A, Hamill D, Kaeding AJ, Meshinchi S, Olson JM, Kolb EA, Barwe SP.
PMID: 34885074
Cancers (Basel). 2021 Nov 26;13(23). doi: 10.3390/cancers13235964.

Advances in the treatment of pediatric AML have been modest over the past four decades. Despite maximally intensive therapy, approximately 40% of patients will relapse. Novel targeted therapies are needed to improve outcomes. We identified mesothelin (MSLN), a well-validated...

Cite
Gopalakrishnapillai A, Correnti CE, Pilat K, et al. Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies. Cancers (Basel). 2021;13(23)doi: 10.3390/cancers13235964.
Gopalakrishnapillai, A., Correnti, C. E., Pilat, K., Lin, I., Chan, M. K., Bandaranayake, A. D., Mehlin, C., Kisielewski, A., Hamill, D., Kaeding, A. J., Meshinchi, S., Olson, J. M., Kolb, E. A., & Barwe, S. P. (2021). Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies. Cancers, 13(23), . https://doi.org/10.3390/cancers13235964
Gopalakrishnapillai, Anilkumar, et al. "Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies." Cancers vol. 13,23 (2021). doi: https://doi.org/10.3390/cancers13235964
Gopalakrishnapillai A, Correnti CE, Pilat K, Lin I, Chan MK, Bandaranayake AD, Mehlin C, Kisielewski A, Hamill D, Kaeding AJ, Meshinchi S, Olson JM, Kolb EA, Barwe SP. Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies. Cancers (Basel). 2021 Nov 26;13(23). doi: 10.3390/cancers13235964. PMID: 34885074; PMCID: PMC8657033.
Copy Download .nbib Format: NLM
Anticipating the primary care role in genomic medicine: expectations of genetics health professionals.

Journal of community genetics

Carroll JC, Morrison S, Miller FA, Wilson BJ, Permaul JA, Allanson J.
PMID: 34379295
J Community Genet. 2021 Oct;12(4):559-568. doi: 10.1007/s12687-021-00544-1. Epub 2021 Aug 11.

Our purpose was to explore genetics health professionals' (GHPs) expectations of primary care providers' (PCPs) role in genomic medicine now and in the future. Focus groups/interviews were conducted with GHPs in Ontario, Canada. Recordings were transcribed and analysed using...

Cite
Carroll JC, Morrison S, Miller FA, et al. Anticipating the primary care role in genomic medicine: expectations of genetics health professionals. J Community Genet. 2021;12(4):559-568doi: 10.1007/s12687-021-00544-1.
Carroll, J. C., Morrison, S., Miller, F. A., Wilson, B. J., Permaul, J. A., & Allanson, J. (2021). Anticipating the primary care role in genomic medicine: expectations of genetics health professionals. Journal of community genetics, 12(4), 559-568. https://doi.org/10.1007/s12687-021-00544-1
Carroll, June C, et al. "Anticipating the primary care role in genomic medicine: expectations of genetics health professionals." Journal of community genetics vol. 12,4 (2021): 559-568. doi: https://doi.org/10.1007/s12687-021-00544-1
Carroll JC, Morrison S, Miller FA, Wilson BJ, Permaul JA, Allanson J. Anticipating the primary care role in genomic medicine: expectations of genetics health professionals. J Community Genet. 2021 Oct;12(4):559-568. doi: 10.1007/s12687-021-00544-1. Epub 2021 Aug 11. PMID: 34379295; PMCID: PMC8554873.
Copy Download .nbib Format: NLM
Collaborative care for depression management in primary care: A randomized roll-out trial using a type 2 hybrid effectiveness-implementation design.

Contemporary clinical trials communications

Smith JD, Fu E, Rado J, Rosenthal LJ, Carroll AJ, Atlas JA, Carlo AD, Burnett-Zeigler I, Jordan N, Brown CH, Csernansky J.
PMID: 34401595
Contemp Clin Trials Commun. 2021 Jul 26;23:100823. doi: 10.1016/j.conctc.2021.100823. eCollection 2021 Sep.

BACKGROUND: The Collaborative Care Model (CoCM) is a well-established treatment for depression in primary care settings. The critical drivers and specific strategies for improving implementation and sustainment are largely unknown. Rigorous pragmatic research is needed to understand CoCM implementation...

Cite
Smith JD, Fu E, Rado J, et al. Collaborative care for depression management in primary care: A randomized roll-out trial using a type 2 hybrid effectiveness-implementation design. Contemp Clin Trials Commun. 2021;23:100823doi: 10.1016/j.conctc.2021.100823.
Smith, J. D., Fu, E., Rado, J., Rosenthal, L. J., Carroll, A. J., Atlas, J. A., Carlo, A. D., Burnett-Zeigler, I., Jordan, N., Brown, C. H., & Csernansky, J. (2021). Collaborative care for depression management in primary care: A randomized roll-out trial using a type 2 hybrid effectiveness-implementation design. Contemporary clinical trials communications, 23100823. https://doi.org/10.1016/j.conctc.2021.100823
Smith, Justin D, et al. "Collaborative care for depression management in primary care: A randomized roll-out trial using a type 2 hybrid effectiveness-implementation design." Contemporary clinical trials communications vol. 23 (2021): 100823. doi: https://doi.org/10.1016/j.conctc.2021.100823
Smith JD, Fu E, Rado J, Rosenthal LJ, Carroll AJ, Atlas JA, Carlo AD, Burnett-Zeigler I, Jordan N, Brown CH, Csernansky J. Collaborative care for depression management in primary care: A randomized roll-out trial using a type 2 hybrid effectiveness-implementation design. Contemp Clin Trials Commun. 2021 Jul 26;23:100823. doi: 10.1016/j.conctc.2021.100823. eCollection 2021 Sep. PMID: 34401595; PMCID: PMC8350002.
Copy Download .nbib Format: NLM
Showing 625 to 631 of 631 entries